Cancer Center researcher Max S. Wicha has received a $6.5 million Outstanding Investigator Award to study cancer stem cells, the small number of cells within a tumor that fuel its growth and spread.
New studies add to questions about predicting whether tamoxifen will be effective in an individual breast cancer patient.
Patients being treated for breast cancer at the University of Michigan Comprehensive Cancer Center now have a new way to help manage the overload of information and reminders that comes with cancer diagnosis, surgery, chemotherapy or radiation treatment.
A small, implantable device that researchers are calling a cancer “super-attractor” could eventually give doctors an early warning of relapse in breast cancer patients and even slow the disease’s spread to other organs in the body.
Concerns about fertility kept a third of young women with breast cancer from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer coming back.
The University of Michigan Comprehensive Cancer Center’s Breast Oncology Program was one of nine beneficiaries of the 2014 QVC Presents "FFANY Shoes on Sale" event. FFANY and QVC representatives presented a check for $380,000 to the Cancer Center.
A survey of women with breast cancer found that nearly half considered having a double mastectomy. But of those who considered it, only 37 percent knew that the more aggressive procedure does not improve survival for women with breast cancer.
Lisa A. Newman, M.D., M.P.H., director of the Breast Care Center, is one of seven University of Michigan faculty members to receive the 2015 Harold R. Johnson Diversity Service Award from the Office of the Provost.